Dysuria

Pipeline Programs↗

Active Trials↗

Companies Involved↗

Dysuria is an early-stage landscape with 8 programs across 2 companies. The most active players are Eli Lilly, Astellas. 3 therapies are approved with 4 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

34/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Eli Lilly

1 program

Approved

Astellas

1 program

Preclinical

Pipeline

Programs by Phase

Preclinical1

Tamsulosin OCAS

Astellas

Phase 1

No programs

Phase 2

No programs

Phase 34

Pílulas De Lussen

Laboratorios Osorio de Moraes Ltda.

Pyridium

Texas Tech University Health Sciences Center

Phenazopyridine

University of Massachusetts, Worcester

Methenamine and Methylthioninium Chloride

EMS

Approved3

Methylene Blue

Provepharm SAS

Lidocaine

MEDRx USA, Inc.

Tadalafil

Eli Lilly

Analysis

Trial Status

clinical trials

Unknown status1 · 33%

Completed1 · 33%

Recruiting1 · 33%

Clinical Trials

Trial Activity

Study to Assess the Efficacy and Safety of "Pílulas de Lussen®" Compared to the Pyridium® in the Symptomatic Control of Dysuria

Unknown status·LLaboratorios Osorio de Moraes Ltda.·Phase 3·NCT00969254·80 enrolled

Efficacy Study of Methenamine + Methylthioninium Chloride vs Phenazopyridine for the Symptomatic Control of Dysuria

Completed·EEMS·Phase 3·NCT01657448·316 enrolled

Management of Dysuria and Irritative Symptoms After HoLEP: a Prospective Study Evaluating the Efficacy of Alpha-Blocker Therapy

Recruiting·—·N/A·NCT06865430·82 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)